<DOC>
	<DOCNO>NCT01548573</DOCNO>
	<brief_summary>This study design decrease toxicity associate prior tandem transplant protocol reduce intensity induction , consolidation maintenance therapy , increase event-free survival add bortezomib ( Velcade® ) , thalidomide , gemcitabine carmustine transplant regimens down-regulate rescue myeloma cell micro-environment prevent DNA repair post high-dose alkylating agent therapy . By reduce drug resistance , hop 3-year event-free survival increase significantly compare Total Therapy II . Additionally , participant option provide biospecimens sub-study evaluate gene expression profile specific timepoints well understand drug-resistance myeloma , determine whether gene gene product resistant population target novel therapy .</brief_summary>
	<brief_title>Tandem Auto Transplantation Myeloma Patients With &lt; 12 Months Prior Treatment</brief_title>
	<detailed_description>This study target towards patient diagnose Multiple Myeloma , POEMS ( Polyneuropathy , organomegaly , endocrinopathy , monoclonal gammopathy , skin change ) , myeloma plus amyloidosis 12 month prior treatment . Furthermore , participant prior autologous allogeneic transplant . The study schema consist one round induction chemotherapy , two transplant , one round consolidation chemotherapy , two year maintenance treatment . This study design differs historical predecessor follow manner : - In contrast Total Therapy II III , allow enrollment patient one cycle one month treatment prior enrollment , propose study allow enrollment participant 12 month prior treatment . - Induction therapy reduce single cycle . - Bortezomib thalidomide add transplant regimen . - Carmustine add second transplant . - Gemcitabine add second transplant regimen . - Consolidation treatment reduce single cycle . - The first year maintenance consist 12 28-day cycle bortezomib , dexamethasone , either thalidomide , lenalidomide , cyclophoshamide . The second year maintenance therapy consist lenalidomide dexamethasone . - The novel agent thalidomide bortezomib introduce upfront , transplantation , consolidation , maintenance .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<criteria>1 . Participants must diagnosis symptomatic MM , MM + amyloidosis , POEMS ( osteosclerotic myeloma : Polyneuropathy , Organomegaly , Endocrinopathy , Monoclonal protein , Skin change ) require treatment . Participants previous history smolder myeloma eligible evidence progressive disease require chemotherapy . Note study participant need active disease time study entry , participant may receive 12 month prior chemotherapy , might induce response . 2 . Protein criterion must present ( quantifiable Mcomponent IgG , IgA , IgD , IgE and/or urinary kappa lambda light chain , BenceJones protein , Free Kappa Light Chain Free Lambda Light Chain ) order evaluate response . Nonsecretory participant eligible provide participant &gt; 20 % plasmacytosis OR multiple ( &gt; 3 ) focal plasmacytoma focal lesion MRI . 3 . Participants must receive 12 month prior chemotherapy disease . Participants may receive prior radiotherapy provide approval obtain PI . 4 . Participants must prior transplant . 5 . Participants must 1880 year age time study entry . 6 . Ejection fraction ECHO MUGA ≥ 40 % perform . 7 . Participants must adequate pulmonary function study , &gt; 50 % predict mechanical aspect ( FEV1 , FVC ) diffusion capacity ( DLCO ) &gt; 50 % predict ( adjusted hemoglobin ) . If participant unable complete pulmonary function test due disease relate pain condition , participant may still enrol provided PI enrol investigator document participant transplant candidate . 8 . Participants must creatinine &lt; 3 mg/dl calculate creatinine clearance &gt; 30mL/min . The CockroftGault equation may use obtain calculated creatinine clearance . 9 . Participants must performance status 02 base ECOG criterion . Participants poor performance status ( 34 ) base solely bone pain eligible , provided documentation verify . 10 . Participants must sign current IRBapproved study ICF ( Informed Consent Form ) . 1 . Prior autologous allogeneic transplant . 2 . Platelet count &lt; 30 x 109/L , unless myelomarelated . If MMrelated , enrol investigator must document . 3 . &gt; grade 3 neuropathy . 4 . Known hypersensitivity bortezomib , boron , mannitol . 5 . Uncontrolled diabetes . 6 . Recent ( &lt; 6 month ) myocardial infarction , unstable angina , difficult control congestive heart failure , uncontrolled hypertension , difficult control cardiac arrhythmia . 7 . Participants must light chain deposition diseaserelated renal failure creatinine &gt; 3 mg/dl . 8 . Participants must concurrent malignancy unless adequately treated surgical , nonchemotherapeutic intervention . Participants may history prior malignancy , provide he/she treatment within 365 day study entry AND life expectancy exceed 5 year time study entry . 9 . Participants must lifethreatening comorbidities . 10 . Women childbearing potential must document negative pregnancy test document within one week study entry . Women men reproductive potential may participate unless agree , sign study ICF , use effective contraceptive method ( ) outline form .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>POEMS ( Polyneuropathy , organomegaly , endocrinopathy , monoclonal gammopathy , skin change )</keyword>
	<keyword>amyloidosis</keyword>
	<keyword>bone marrow transplant</keyword>
	<keyword>autologous</keyword>
</DOC>